SGLT2 inhibitor for prediabetes complications
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 35 and 75 years old.
- You have prediabetes (high blood sugar but not diabetes).
- Your body mass index (BMI) is 20 or higher.
- Your thyroid hormone levels are normal.
- You are not currently taking medications for diabetes or certain other drugs that affect blood sugar.
- You are willing to use effective birth control if needed and follow study instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
This study tests whether a once-daily pill (henagliflozin) can help people with prediabetes return to normal blood sugar levels. If it works, it might prevent prediabetes from progressing to type 2 diabetes.
This study tests a medication called dapagliflozin, which is usually for type 2 diabetes, to see if it can be used safely in people with type 1 diabetes. It focuses on preventing a serious side effect called ketoacidosis, where the blood becomes too acidic.
This trial tests a medication called dapagliflozin (often used in type 2 diabetes) to see if it can help protect the kidneys in people with type 1 diabetes who already have some signs of kidney damage. If it works, it could slow down further kidney decline.
This study looks at adults with prediabetes—specifically abnormal fasting and/or 2-hour blood sugar tests—to see whether a treatment helps improve sugar control. You may also be compared with people who have normal blood sugar (the control group).
Hear when a new Type2diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.